

WEST**Freeform Search****Database:**

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:
Display: **Documents in Display Format:** **Starting with Number**
Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History
DATE: Tuesday, November 26, 2002 [Printable Copy](#) [Create Case](#)
Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

<u>L54</u>	L50 same (microsphere or microcapsule or microparticulate) same (cross near link\$)	23	<u>L54</u>
<u>L53</u>	L51 and (phospholipids or lecithin)	97	<u>L53</u>
<u>L52</u>	L51 and (phospholipids)	69	<u>L52</u>
<u>L51</u>	L50 same (microsphere or microcapsule or microparticulate)	626	<u>L51</u>
<u>L50</u>	(PLGA or PLA or (polyanhydrides) or polylactic polymers) same calcium	30329	<u>L50</u>
<u>L49</u>	L48 and (lecithin or phospholipids)	3	<u>L49</u>
<u>L48</u>	L47 same (microsphere or microcapsule or microparticulate)	14	<u>L48</u>
<u>L47</u>	(PLGA or PLA or (polyanhydrides) or polylactic) same calcium	656	<u>L47</u>
<u>L46</u>	(calcium) same (cross near linking) same (liposomes)	7	<u>L46</u>
<u>L45</u>	(calcium) same (cross near linking) same (lipids or phospholipids or lecithin)	26	<u>L45</u>
<u>L44</u>	5855913.pn. and buffer	0	<u>L44</u>
<u>L43</u>	L41 same((pulmonary or lung) near delivery)	6	<u>L43</u>

<u>L42</u>	L41 same phospholipids	92	<u>L42</u>
<u>L41</u>	(matrix or microsphere or microcapsules) same (ions or salts)	30662	<u>L41</u>
<u>L40</u>	L39 and (lung or pulmonary)	13	<u>L40</u>
<u>L39</u>	L38 and (microparticulate or microsphere or matrix or microcapsule)	87	<u>L39</u>
<u>L38</u>	L36 same (phospholipids or lecithin or \$choline)	347	<u>L38</u>
<u>L37</u>	L36 and (microparticulate or microsphere or matrix or microcapsule)	8688	<u>L37</u>
<u>L36</u>	particles same calcium	39327	<u>L36</u>
<u>L35</u>	L34 and (aerosol or pulmonary or lung)	59	<u>L35</u>
<u>L34</u>	matrix same calcium same (\$lipids or lipids or lecithin)	188	<u>L34</u>
<u>L33</u>	matrix same calcium same (\$lipids or lipids)	148	<u>L33</u>
<u>L32</u>	L31 and phospholipids	42	<u>L32</u>
<u>L31</u>	(microparticulate or microsphere or matrix or microcapsule) same calcium same stabil\$	686	<u>L31</u>
<u>L30</u>	L24 and (pulmonary or lung or aerosol)	355	<u>L30</u>
<u>L29</u>	L24 and (pulmonary near delivery)	16	<u>L29</u>
<u>L28</u>	L24 and (pulmonary or respiratory or lung or inhalation or inhale)	344	<u>L28</u>
<u>L27</u>	L25 and (pulmonary or respiratory or lung or inhalation)	32	<u>L27</u>
<u>L26</u>	L25 and (pulmonary or respiratory or lung)	29	<u>L26</u>
<u>L25</u>	L23 same (lecithin or phospholipids)	95	<u>L25</u>
<u>L24</u>	L23 and phospholipids	555	<u>L24</u>
<u>L23</u>	(microparticulate or microsphere or matrix or microcapsule) same calcium	9405	<u>L23</u>
<u>L22</u>	l18 same phospholipids	39	<u>L22</u>
<u>L21</u>	L19 and phospholipids	16	<u>L21</u>
<u>L20</u>	L19 and lipids	24	<u>L20</u>
<u>L19</u>	L18 and (pulmonary near delivery)	25	<u>L19</u>
<u>L18</u>	(matrix or microsphere or microcapsules) same calcium	9293	<u>L18</u>
<u>L17</u>	(matrix or microsphere or microcapsules) and calcium	52950	<u>L17</u>
<u>L16</u>	5580575.pn. and calcium	1	<u>L16</u>
<u>L15</u>	5648095.pn. and calcium	0	<u>L15</u>
<u>L14</u>	5955143.pn. and calcium	0	<u>L14</u>
<u>L13</u>	5855913.pn. and lactose	1	<u>L13</u>
<u>L12</u>	L9 and Ca	1	<u>L12</u>
<u>L11</u>	L9 and Ca	1	<u>L11</u>
<u>L10</u>	L9 and calcium	0	<u>L10</u>
<u>L9</u>	L8 near justin	16	<u>L9</u>
<u>L8</u>	hanes.in.	889	<u>L8</u>
<u>L7</u>	l6 and (pulmonary or lung or respiratory)	18	<u>L7</u>
<u>L6</u>	L5 same (matrix or microsphere or microcapsules)	39	<u>L6</u>
<u>L5</u>	phospholipids same calcium	2106	<u>L5</u>
<u>L4</u>	L3 and calcium	91	<u>L4</u>
<u>L3</u>	L2 and (microspheres or microcapsules or matrix)	133	<u>L3</u>

<u>L2</u>	L1 and (pulmonary near delivery)	324	<u>L2</u>
<u>L1</u>	(phospholipids) and (inhalation or inhaler or aerosol)	5493	<u>L1</u>

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L4: Entry 1 of 2

File: USPT

Apr 23, 1996

DOCUMENT-IDENTIFIER: US 5510112 A

TITLE: Composition for enhancing the biodegradation of biodegradable organic wastes

Brief Summary Text (51):

The phospholipids are classified according to their polar headgroups into two major classes: 1) neutral-zwitterionic phosphatidylcholine (PC) referred to as lecithin; 2) less hydrophobic-amphoterics phospholipids such as phosphatidylethanolamine (PE), and 3) negatively-charged phospholipids such as phosphatidylglycerol (PG) or phosphatidylinositol (PI). While the cost of crude phospholipids (e.g. from soybean or rapeseed) is less than \$1 per kg, that of highly purified lecithin may be a thousand fold or even more expensive.

WEST

Generate Collection

Print

L13: Entry 25 of 37

File: USPT

Sep 5, 2000

DOCUMENT-IDENTIFIER: US 6114107 A

TITLE: Composition comprising raffinose, TMAO, sodium citrate and methods for the preservation of living tissues

Brief Summary Text (7):

The viability of biological materials stored in saline-based media gradually decreases over time. Loss of viability is believed to be due to the build-up of toxic wastes, and loss of metabolites and other supporting compounds caused by continued metabolic activity. Using conventional saline-based media, living tissues can only be successfully preserved for relatively short periods of time. Examination of the microstructure of organs stored towards the upper limit of time shows degeneration, such as of mitochondria in heart muscle, and the performance of the organ once replaced is measurably compromised. For example, a human heart can only be stored in cold ionic solutions for about 5 hours following removal from a donor, thereby severely limiting the distance over which the heart can be transported.

Drawing Description Text (42):

As detailed below, it has been determined that, with the exception of platelets, effective storage times for biological materials increase with the addition of calcium to the preservative compositions. This may be due to the ability of calcium to stabilize phospholipid bilayers found in cell membranes and to stabilize intercellular adhesion. Preferably the calcium is present as calcium sulfate or calcium chloride, and is present at a concentration greater than about 1.5 mM or less than about 2.0 mM, more preferably at a concentration of between about 1.5 mM and about 2.0 mM, and most preferably about 1.75 mM. The addition of either sodium sulfate or sodium citrate also increases effective storage times for many biological materials. A composition comprising between about 60% and about 80%, preferably about 70%, raffinose and TMAO, between about 40% and about 20%, preferably about 30% sodium sulfate, and about 1.75 mM calcium sulfate, with the raffinose and TMAO being present in a ratio of about 1.6:1 has been found to be particularly effective in preserving many biological materials.

WEST



Generate Collection

Print

L13: Entry 34 of 37

File: USPT

May 14, 1996

US-PAT-NO: 5516662

DOCUMENT-IDENTIFIER: US 5516662 A

TITLE: Process for the preparation of headgroup-modified phospholipids using
phosphatidylhydroxyalkanols as intermediates

DATE-ISSUED: May 14, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Singh; Alok	Springfield	VA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
The United States of America as represented by the Secretary of the Navy	Washington	DC			06	

APPL-NO: 08/ 439074 [PALM]

DATE FILED: May 11, 1995

PARENT-CASE:

This is a division of application Ser. No. 08/099,639, filed Jul. 30, 1993, now U.S.
Pat. No. 5,441,876, to Alok Singh, titled PROCESS FOR THE PREPARATION OF
HEADGROUP-MODIFIED PHOSPHOLIPIDS USING PHOSPHATIDYLHYDROXYALKANOLS AS INTERMEDIATES.

INT-CL: [06] C12 P 9/00

US-CL-ISSUED: 435/131

US-CL-CURRENT: 435/131

FIELD-OF-SEARCH: 435/131, 554/78, 554/79

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>4235792</u>	November 1980	Hsia et al.	260/403
<input type="checkbox"/>	<u>4382035</u>	May 1983	Eibl	260/403
<input type="checkbox"/>	<u>4587055</u>	May 1986	Regen	260/413
<input type="checkbox"/>	<u>4624919</u>	November 1986	Kokusho et al.	435/74
<input type="checkbox"/>	<u>4783402</u>	November 1988	Kokusho et al.	435/52
<input type="checkbox"/>	<u>4849019</u>	July 1989	Yasukawa et al.	106/244
<input type="checkbox"/>	<u>4933114</u>	June 1990	O'Brien et al.	260/403
<input type="checkbox"/>	<u>5011964</u>	April 1991	Mynarcik et al.	558/179
<input type="checkbox"/>	<u>5080911</u>	January 1992	Saitou et al.	426/32
<input type="checkbox"/>	<u>5183750</u>	February 1993	Nishide et al.	435/134
<input type="checkbox"/>	<u>5188951</u>	February 1993	Tremblay et al.	435/131

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
200403	April 1986	EP	
62-205788	September 1987	JP	
1581810	December 1980	GB	
831129	May 1981	SU	
WO89/01524	February 1989	WO	

OTHER PUBLICATIONS

Mank et al., "Synthesis of acyl di-and triglycerols", Chemistry and Physics of Lipids, vol. 50, 1989, pp. 63-70.

Singh et al., "Phosphatidylhydroxyalkanols As Versatile Intermediates In The Synthesis Of Headgroup Modified Diacetylenic Phospholipids", Synthetic Communications, vol. 22, No. 16, Sep. 1992, pp. 2293-2304.

Achterberg et al., "Conversion Of Radiolabelled Ethanolamine Plasmalogen Into The Dimethylethanolamine And Choline Analogue Via Transphosphatidylation By Phospholipase D From Cabbage", Chemistry and Physics of Lipids, vol. 41, 1986, pp. 349-353.

Yang et al., "Transphosphatidylation by Phospholipase D", J. Biol. Chem., vol. 242, No. 3, 1966, pp. 477-484.

Chrastil et al., "Phospholipases C and D in Rice Grains", J. Agric. Food Chem., vol. 35, No. 4, 1987, pp. 624-627.

Shuto et al., "A Facile One-Step Synthesis Of Phosphatidylhomoserines By Phospholipase D-Catalyzed Transphosphatidylation", Chem. Pharm. Bull., vol. 25, No. 1, 1987, pp. 447-449.

Ali et al., "Mixed-chain phosphatidylcholine analogues modified in the choline moiety: preparation of isomerically pure phospholipids with bulky head groups and one acyl chain twice as long as the other", Chemistry and Physics of Lipids, vol. 50, 1989, pp. 11-21.

Juneja et al., "Repeated batch and continuous operations for phosphatidylglycerol synthesis from phosphatidylcholine with immobilized phospholipase D", Appl. Microbiol. Biotechnol., vol. 27, 1987, pp. 146-151.

Juneja et al., "Comparative study on conversion of phosphatidylchlorine to phosphatidylcylcerol by cabbage phospholipase D in micelle and emulsion systems", Enzyme and Microbiol. Technol., vol. 9, No. 6, 1987, pp. 350-354.

Markowitz, MA et al., Cheml Phys. Lipids 62:193-204 (1992).

Manyemana, F. et al. Tetrahedron Lett. 30:3077-80 (1989).

Nan, Z. et al., Huaxue Shiji 14:117-18 (1992).

ART-UNIT: 188

PRIMARY-EXAMINER: Wityshyn; Michael G.

ASSISTANT-EXAMINER: Saucier; S.

ATTY-AGENT-FIRM: McDonnell; Thomas E. Edelberg; Barry A.

ABSTRACT:

Phospholipase D enzyme is used to mediate the synthesis of a phosphatidylhydroxyalkanol in a first step. This phosphatidylhydroxyalkanol is reacted to produce a headgroup modified phospholipid in a subsequent step. In the first step, phospholipase D enzyme extract mediates transphosphatidylation of a phospholipid with an alcohol containing at least two hydroxyl groups per molecule, producing reproducible and nearly quantitative yields of a phosphatidylhydroxyalkanol. In the subsequent step, the hydroxyl head group of the phosphatidylhydroxyalkanol is further reacted with amino, carboxylic, halogen or thiol containing molecules to produce a headgroup modified phospholipid.

2 Claims, 0 Drawing figures